newsfilter
← Latest News
Business Wire·

Quince Therapeutics Provides Business Update and Reports Fiscal Year 2024 Financial Results

Phase 3 NEAT clinical trial exceeds 50% enrollment with new study site activations expected to accelerate screenings and randomization Existing cash position of $40.8 million expected to provide operating runway